Randall Kaye compensation by year
Longboard Pharmaceuticals Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $351,563 | $472,500 |
| Bonus | $0 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $827,115 | $443,113 |
| Non-equity incentive | $198,000 | $228,690 |
| Pension and deferred compensation | $0 | $0 |
| All other | $9,150 | $16,764 |
| Total | $1,385,828 | $1,161,067 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Longboard Pharmaceuticals, Inc. DEF 14A filed April 12, 2024, accession 0000950170-24-044023, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Longboard Pharmaceuticals, Inc. filed document, accession 0000950170-24-044023. Every figure is read from that document and cited to the page and table it appears in. Filed April 12, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 116,157 | — | $6.00 |
| Option | 115,821 | — | $4.35 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Longboard Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
24 Form 4 lines since the FY2023 proxy (filed April 12, 2024)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2024-12-02 | Disposition to the issuer derivative | — | 9,500 | — | 0 |
| 2024-12-02 | U | — | 30,554 | $60.00 | 0 |
| 2024-12-02 | Disposition to the issuer derivative | — | 175,946 | — | 0 |
| 2024-12-02 | Disposition to the issuer derivative | — | 17,920 | — | 0 |
| 2024-12-02 | Disposition to the issuer derivative | — | 107,560 | — | 0 |
| 2024-12-02 | Disposition to the issuer derivative | — | 96,300 | — | 0 |
| 2024-11-19 | Exercise or conversion | — | 30,554 | $6.00 | 48,474 |
| 2024-11-19 | Exercise or conversion derivative | — | 30,554 | $0.00 | 175,946 |
The 8 most recent of 24 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Longboard Pharmaceuticals’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Kevin Lind | President and Chief Executive Officer | $2,053,804 |
| Randall Kaye · this page | Executive Vice President and Chief Medical Officer | $1,161,067 |
| Brandi Roberts | Executive Vice President and Chief Financial Officer | $1,025,200 |
Randall Kaye's compensation dossier, Longboard Pharmaceuticals
You have read Randall Kaye's totals and holdings. The dossier adds each equity grant Longboard Pharmaceuticals disclosed for Randall Kaye and Longboard Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Longboard Pharmaceuticals compensation record
free company briefThis page is one person within Longboard Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Longboard Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.